Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa Study of AK106-001616 vs Naproxen in Rheumatoid Arthritis
2010-021558-21Phase 2Completed
- Sponsor
- Asahi Kasei Corporation
- Start
- Oct 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of AK106-001616 in rheumatoid arthritis (RA) (3 arms), sponsored by Asahi Kasei Corporation. Primary endpoints: Clinically relevant improvement in anti-inflammatory/analgesic activity and Safety and efficacy via pharmacodynamic urinary biomarkers. Started Oct 2010; status: completed.
02
Drugs
AK106-001616
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2010-021558-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021558-21.